Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer.
A considerable number of gastric cancers derive from stomach mucosa where chronic atrophic gastritis is severe and extensive.
Based on the fact that the serum pepsinogen levels provide a precise measure of the extent of chronic atrophic gastritis, we have devised a mass screening method involving serum pepsinogen measurement to identify subjects at high risk of gastric cancer.
In 1991, we screened 4,647 workers (male: 4,113, female: 534, mean age: 49.0 years) at a Japanese company using this method.
Out of 875 subjects (18.8%) with a serum pepsinogen I level of less than 50 mug/liter and a pepsinogen I/II ratio of less than 3.0, 676 subjects (14.5%) were selected for further investigation by endoscopy.
Mots-clés Pascal : Tumeur maligne, Estomac, Dépistage, Pepsin A, Aspartic endopeptidases, Proteinases, Hydrolases, Enzyme, Zymogène, Sérum, Japon, Asie, Diagnostic, Epidémiologie, Homme, Estomac pathologie, Appareil digestif pathologie
Mots-clés Pascal anglais : Malignant tumor, Stomach, Medical screening, Pepsin A, Aspartic endopeptidases, Proteinases, Hydrolases, Enzyme, Zymogen, Serum, Japan, Asia, Diagnosis, Epidemiology, Human, Gastric disease, Digestive diseases
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 94-0063643
Code Inist : 002B13B01. Création : 199406.